{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000077","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.735960+00:00","generated_at":"2026-05-19T04:56:47.886537+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports interim Phase 2a data: 39% ORR, 81% DCR in first-line pancreatic cancer","bullets":["As of May 26, 2025 cutoff: 1 CR, 13 PR (4 pending confirmation), 15 SD among 36 evaluable patients; DCR 81%, ORR 39%.","In 320 mg ITT population (n=34): 94% OS and 72% PFS at 6 months median follow-up; median OS and PFS not reached.","Grade≥3 TEAEs in ≥10% of 320 mg patients: anemia (18%) and neutropenia (15%); no Grade 5 events.","Additional data expected Q4 2025; pivotal trial of atebimetinib+mGnP in 1L pancreatic cancer planned for 2026, pending regulatory feedback Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000077","json":"https://secwatch.observer/filing/0001790340-25-000077.json","markdown":"https://secwatch.observer/filing/0001790340-25-000077.md","text":"https://secwatch.observer/filing/0001790340-25-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/0001790340-25-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000077/imrx-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:56:47.886537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}